AU2022207756B2 - Solid tablet dosage form of ridinilazole - Google Patents

Solid tablet dosage form of ridinilazole

Info

Publication number
AU2022207756B2
AU2022207756B2 AU2022207756A AU2022207756A AU2022207756B2 AU 2022207756 B2 AU2022207756 B2 AU 2022207756B2 AU 2022207756 A AU2022207756 A AU 2022207756A AU 2022207756 A AU2022207756 A AU 2022207756A AU 2022207756 B2 AU2022207756 B2 AU 2022207756B2
Authority
AU
Australia
Prior art keywords
ridinilazole
tablet
tetrahydrate
diluent
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2022207756A
Other languages
English (en)
Other versions
AU2022207756A9 (en
AU2022207756A1 (en
Inventor
Jean-Francois Carniaux
Peter Timmins
Laura Trespidi
Francis X. Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Summit (oxford) Ltd
Original Assignee
Summit Oxford Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Summit Oxford Ltd filed Critical Summit Oxford Ltd
Publication of AU2022207756A1 publication Critical patent/AU2022207756A1/en
Publication of AU2022207756A9 publication Critical patent/AU2022207756A9/en
Application granted granted Critical
Publication of AU2022207756B2 publication Critical patent/AU2022207756B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2022207756A 2021-01-14 2022-01-14 Solid tablet dosage form of ridinilazole Active AU2022207756B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2100470.0A GB202100470D0 (en) 2021-01-14 2021-01-14 Solid tablet dosage for of ridinilazole
GB2100470.0 2021-01-14
PCT/IB2022/050311 WO2022153246A1 (en) 2021-01-14 2022-01-14 Solid tablet dosage form of ridinilazole

Publications (3)

Publication Number Publication Date
AU2022207756A1 AU2022207756A1 (en) 2023-07-27
AU2022207756A9 AU2022207756A9 (en) 2024-05-09
AU2022207756B2 true AU2022207756B2 (en) 2026-01-15

Family

ID=74679044

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022207756A Active AU2022207756B2 (en) 2021-01-14 2022-01-14 Solid tablet dosage form of ridinilazole

Country Status (12)

Country Link
US (1) US12318487B2 (https=)
EP (1) EP4277604A1 (https=)
JP (1) JP2024503689A (https=)
KR (1) KR20230131253A (https=)
CN (1) CN116801867A (https=)
AU (1) AU2022207756B2 (https=)
CA (1) CA3145677A1 (https=)
GB (1) GB202100470D0 (https=)
IL (1) IL304354A (https=)
MX (1) MX2023008249A (https=)
WO (1) WO2022153246A1 (https=)
ZA (1) ZA202306739B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023213878A1 (en) * 2022-05-04 2023-11-09 Summit (Oxford) Limited Solid tablet dosage form of ridinilazole

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160184283A1 (en) * 2008-12-02 2016-06-30 Summit Therapeutics Plc Antibacterial compounds
WO2016120258A1 (en) * 2015-01-27 2016-08-04 Janssen Pharmaceutica Nv Dispersible compositions
WO2019068383A1 (en) * 2017-10-05 2019-04-11 Sandoz Ag PROCESS FOR THE PREPARATION OF RIDINILAZOLE USING ACID ADDITION SALTS

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996016042A1 (de) 1994-11-17 1996-05-30 F. Hoffmann-La Roche Ag Antibakterielle dibenzimidazol-derivate
HUP0303494A3 (en) 2000-12-15 2009-08-28 Vertex Pharma Parmaceutical compositions containing bacterial gyrase inhibitors and uses thereof
DE60309701T2 (de) 2002-06-13 2007-09-06 Vertex Pharmaceuticals Inc., Cambridge 2-ureido-6-heteroaryl-3h-benzoimidazol-4-carbonsäurederivate und verwandte verbindungen als gyrase und/oder topoisomerase iv inhibitoren zur behandlung von bakteriellen infektionen
WO2004041209A2 (en) 2002-11-01 2004-05-21 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
EP1742637A4 (en) 2004-04-23 2011-06-08 Paratek Pharm Innc TRANSCRIPTION FACTOR MODULATION COMPOUNDS AND METHODS OF USE
US7825154B2 (en) 2005-08-12 2010-11-02 The United States Of America As Represented By The Secretary Of The Army Small molecule inhibitors of botulinum neurotoxins
AU2006311729A1 (en) 2005-11-07 2007-05-18 Vertex Pharmaceuticals Incorporated Benzimidazole derivatives as gyrase inhibitors
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
CA2563690C (en) 2006-10-12 2014-10-07 Pharmascience Inc. Pharmaceutical compositions comprising intra- and extra- granular fractions
FR2918566B1 (fr) * 2007-07-11 2009-10-09 Pierre Fabre Medicament Sa Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine.
EP3315124B1 (en) * 2009-11-13 2021-01-06 Astrazeneca AB Bilayer tablet formulations
ES2568455T3 (es) 2010-06-01 2016-04-29 Summit Therapeutics Plc Compuestos para el tratamiento de enfermedad asociada a Clostridium difficile
WO2011151620A1 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
KR20190140011A (ko) * 2017-04-28 2019-12-18 아사나 바이오사이언시스 엘엘씨 아토피성 피부염을 치료하고, 활성 약학적 성분의 안정성을 개선하기 위한 제형물, 방법, 키트, 및 투여형
KR20210033483A (ko) * 2018-07-19 2021-03-26 다케다 야쿠힌 고교 가부시키가이샤 Cdc7 억제제를 갖는 약제학적 조성물
KR102737283B1 (ko) 2019-07-17 2024-12-03 서밋 (옥스포드) 리미티드 리디닐라졸 및 이의 결정 형태의 제조방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160184283A1 (en) * 2008-12-02 2016-06-30 Summit Therapeutics Plc Antibacterial compounds
WO2016120258A1 (en) * 2015-01-27 2016-08-04 Janssen Pharmaceutica Nv Dispersible compositions
WO2019068383A1 (en) * 2017-10-05 2019-04-11 Sandoz Ag PROCESS FOR THE PREPARATION OF RIDINILAZOLE USING ACID ADDITION SALTS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Remington: The Science and Practice of Pharmacy. 22nd ed.", 1 January 2012, PHP, article REMINGTON J.: "Chapter 45: Oral solid dosage forms", pages: 947, XP055634446 *

Also Published As

Publication number Publication date
AU2022207756A9 (en) 2024-05-09
CN116801867A (zh) 2023-09-22
IL304354A (en) 2023-09-01
MX2023008249A (es) 2023-07-26
US20220226249A1 (en) 2022-07-21
AU2022207756A1 (en) 2023-07-27
ZA202306739B (en) 2025-05-28
US12318487B2 (en) 2025-06-03
GB202100470D0 (en) 2021-03-03
CA3145677A1 (en) 2022-07-14
JP2024503689A (ja) 2024-01-26
EP4277604A1 (en) 2023-11-22
KR20230131253A (ko) 2023-09-12
WO2022153246A1 (en) 2022-07-21

Similar Documents

Publication Publication Date Title
JP7641320B2 (ja) ｓＧＣ刺激薬を含んでなる固体分散剤
KR101641517B1 (ko) Ｂｉｂｗ 2992를 포함하는 약제학적 고체 제형
US20220339111A1 (en) Immediate-release tablets containing a drug and processes for forming the tablets
AU2011316003B2 (en) Pharmaceutical compositions containing a DGAT1 inhibitor
KR20150097792A (ko) 개선된 생체이용률을 갖는 약학 조성물
JP7443543B2 (ja) 医薬組成物
CN105073101B (zh) 具有高含量非索非那定的固体单元及其制备方法
AU2022207756B2 (en) Solid tablet dosage form of ridinilazole
WO2023213878A1 (en) Solid tablet dosage form of ridinilazole
WO2024079245A1 (en) Ridinilazole for treating clostridium difficile
EP3072528B1 (en) Composition comprising vemurafenib and cationic copolymer based on methacrylates
TW202435886A (zh) 米爾維仙(milvexian)醫藥組合物
HK40099995A (en) Immediate-release tablets containing a drug and processes for forming the tablets
HK40061820A (en) Immediate-release tablets containing a drug and processes for forming the tablets
AU2024317636A1 (en) Pharmaceutical composition containing substituted indol-5-ol derivative and use thereof
CN116782888A (zh) 药物组合物
WO2019030773A1 (en) DICLOFENAC COMPOSITIONS WITH LOW DOSE

Legal Events

Date Code Title Description
SREP Specification republished